A phase 2 study of the aurora kinase A inhibitor alisertib for patients with neuroendocrine prostate cancer (NEPC)
Himisha Beltran,Daniel C. Danila,Bruce Montgomery,R. Szmulewitz,Ulka N. Vaishampayan,Andrew J. Armstrong,M. Stein,Christopher J. Hoimes,J. Pinski,Howard I. Scher,Loredana Puca,R. Bareja, W. Wong,Mark A. Rubin,Juan Miguel Mosquera,Andrea Sboner, Clara Oromendia,David M. Nanus,Karla V. Ballman,Scott T. Tagawa ANNALS OF ONCOLOGY（2016）
AI 理解论文
溯源树
样例
